Informações:
Falhas:
ID
17233
Descrição
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00258466
Link
https://clinicaltrials.gov/show/NCT00258466
Palavras-chave
Versões (1)
- 01/09/2016 01/09/2016 -
Transferido a
1 de setembro de 2016
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Prostate Cancer NCT00258466
Eligibility Prostate Cancer NCT00258466
- StudyEvent: Eligibility
Similar models
Eligibility Prostate Cancer NCT00258466
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Adenocarcinoma of the prostate
Item
histologically confirmed adenocarcinoma of the prostate
boolean
C0007112 (UMLS CUI [1])
Tumor stage
Item
stage i-iii disease (t1-t3, n0, m0)
boolean
C1300072 (UMLS CUI [1])
Metastasis
Item
no clinical or radiographic evidence of metastasis
boolean
C0027627 (UMLS CUI [1])
Radioisotope bone scan must show no evidence of metastasis
Item
if prostate-specific antigen (psa) ≥ 10.0 ng/ml and gleason score is 7, a radioisotope bone scan must show no evidence of metastasis
boolean
C0203668 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
C0027627 (UMLS CUI [1,2])
no evidence of lymphatic or visceral metastases
Item
no evidence of lymphatic or visceral metastases of the abdomen or pelvis on ct scan or mri
boolean
C0024232 (UMLS CUI [1])
C0027627 (UMLS CUI [2,1])
C0442045 (UMLS CUI [2,2])
C0027627 (UMLS CUI [2,1])
C0442045 (UMLS CUI [2,2])
PSA
Item
psa ≤ 20 ng/ml
boolean
C0201544 (UMLS CUI [1])
gleason score
Item
gleason score ≤ 7 (if stage t3 , score must be < 7)
boolean
C0332326 (UMLS CUI [1])
patient characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
performance status
Item
performance status: not specified
boolean
C1518965 (UMLS CUI [1])
life expectancy
Item
life expectancy: more than 10 years
boolean
C0023671 (UMLS CUI [1])
hematopoiesis
Item
hematopoietic: not specified
boolean
C0018951 (UMLS CUI [1])
Hepatic function
Item
hepatic: not specified
boolean
C0232741 (UMLS CUI [1])
Renal function
Item
renal: not specified
boolean
C0232804 (UMLS CUI [1])
Malignancy
Item
other: no other malignancy within the past 5 years except basal cell or squamous cell skin cancer
boolean
C0006826 (UMLS CUI [1])
concurrent therapy
Item
prior concurrent therapy:
boolean
C0009429 (UMLS CUI [1])
endocrine therapy
Item
endocrine therapy
boolean
C0279025 (UMLS CUI [1])
Hormonal therapy
Item
prior hormonal therapy allowed provided it was initiated no more than 2 months ago, and may include the following:
boolean
C0279025 (UMLS CUI [1])
luteinizing hormone-releasing hormone agonists
Item
luteinizing hormone-releasing hormone agonists (e.g., goserelin, leuprolide)
boolean
C1518041 (UMLS CUI [1])
anti-androgens
Item
anti-androgens (e.g., flutamide, bicalutamide)
boolean
C0002842 (UMLS CUI [1])
Radiotherapy
Item
radiotherapy
boolean
C1522449 (UMLS CUI [1])
pelvic irradiation
Item
no prior pelvic irradiation
boolean
C0747411 (UMLS CUI [1])
Surgery
Item
surgery
boolean
C0543467 (UMLS CUI [1])
radical prostatectomy
Item
no prior radical prostatectomy
boolean
C0194810 (UMLS CUI [1])